Quarterly Activities Report and Appendix 4C
Filed with ASX ·
6ix is reading this filing.
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- Percheron raises $2.3m to fully fund clinical trial in AML
- Vanderbilt Health to conduct clinical trial of HMBD-002
- Percheron Therapeutics Announces CEO Succession
- Results of Entitlement Offer
- Prospectus - Non-renounceable Entitlement Offer
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics